The VentrAssist U.S. The VentrAssist U.S. Pivotal Bridge to Cardiac Pivotal Bridge to Cardiac
Transplantation TrialTransplantation Trial
A Boyle, N Moazami, R John, G Ewald, A Anyanwu, S Pinney, S Desai, N Burton, J Teuteberg, R Kormos, M Parides, A Gelijns, D Ascheim, U
Rawiel, L Joyce, and the VentrAssist Investigators
University of Minnesota, Washington University, Mt. Sinai School of Medicine, Inova Fairfax Hospital, University of Pittsburgh
Presenter Disclosure InformationAndrew J. Boyle, MD
The following relationships exist related to this presentation:
Scientific Advisor Ventracor no financial relationship
Consulting Fees Thoratec Modest Level
VentrAssist: 1VentrAssist: 1stst Centrifugal LVAD Centrifugal LVADSmall size (298 g)Single moving part - rotorNo valves, diaphragms or mechanical bearingDiamond-like carbon coating on blood contacting surfaces Hydrodynamic suspension (rotor is supported by the blood within the pump)Rotor contains high-strength magnetsController delivers power to copper coils via leadMagnetic forces from the coils spin the rotor
VentrAssist ComponentsVentrAssist Components
Implantable blood pump
Powered via percutaneous lead
Controller logs parameters & alarms
Battery or AC power supply Laptop PC for clinician use
Blood pump
Outflow cannula
Controller and battery receptacle
Percutaneous lead
Inflow cannula
US Feasibility Study OutcomesUS Feasibility Study OutcomesAt 6 months, 86% of patients were transplanted or alive on support
Boyle A et al. ISHLT, Boston, MA, 2008.
Summary
Total number of patients implanted 421
Longest support duration (d) 1594
Mean support duration (d) 219
Number of patients currently supported 180
VentrAssist Support Duration
> 6 months 192
> 12 months 67
> 24 months 16
Worldwide VentrAssist Experience*Worldwide VentrAssist Experience*
* As of 3/3/09
Bridge To Transplant Pivotal Trial DesignBridge To Transplant Pivotal Trial Design
Multi-center, prospective, single-arm studyPerformance goal set by FDA (75% success rate)Null hypothesis: Treatment with VentrAssist LVAD is non-inferior to the Performance Goal Non-inferiority margin = 10%Pre-specified Interim Analysis after 98 outcomes (70%): Null hypothesis rejected if 74 or more successes (observed success rate of 75.5%)
Study EnrollmentStudy EnrollmentTarget Enrollment
n = 144
Pre-specified interim analysis 2/09
98 patients reached endpoint and available for outcomes analysis
138 patients enrolled and available for SAE analysis
One patient received a BiVAD and not a VentrAssist device.One patient received a Thoratec LVAD and not a VentrAssist device.One patient had an esophageal perforation during initial implant procedure and did not receive a VentrAssist device.
EndpointsEndpointsPrimary endpoint:
• Success― Survival to transplantation or ― On support for ≥180 days and listed UNOS 1A/1B
• Failure ― Mortality prior to outcome― Device replacement prior to outcome
Secondary endpoints:• INTERMACS defined SAEs • Quality of life• Functional status• Neurocognitive function
Inclusion CriteriaInclusion Criteria
Age ≥ 18 yrs BSA ≥ 1.5 m2
Approved for transplant & listed as Status 1A or 1B Clinical indication for BTT LVAD
Exclusion CriteriaExclusion Criteria Cardiotomy within 30 days Acute MI within 48 hours Hypertrophic or restrictive cardiomyopathy Prior heart transplant or LVAD Mechanical aortic or mitral valve > 1+ aortic insufficiency Platelets < 80,000 or coagulopathy Anticipated need for RVAD PVR > 8 Woods units Creatinine > 3.5 mg/dl or dialysis Liver function tests > 5 X upper limits of normal Stroke < 90 days Contraindication to anticoagulation
Clinical SitesClinical Sites• University of Minnesota• Washington University• Fairfax Inova• Mt. Sinai• St. Vincent’s Indianapolis• Mayo Clinic• Northwestern University• University of Alabama• University of Pittsburgh• Newark Beth Israel• Allegheny General• Sacred Heart
• University of Florida • Columbia University• Montefiore Hospital• Ohio State University• University of Pennsylvania• University of Utah• Duke University• St. Luke’s Medical Center• University of Maryland• Methodist Hospital• University of Rochester• University of Washington
Baseline CharacteristicsBaseline CharacteristicsN=98
Mean (±SD)N=138
Mean (±SD)
Age (years) 53 (12) 53 (12)
LVEF (%) 18.0 (6.8) 17.5 (6.7)
BP systolic (mmHg) 100.1 (15.7) 100.0 (15.3)
Cardiac Output (l/min) 4.2 (1.3) 4.2 (1.3)
Cardiac Index (l/min/m2) 2.0 (0.6) 2.0 (0.6)
PCWP (mmHg) 24.3 (8.4) 24.8 (8.2)
PVR (Wood Units) 3.1 (2.0) 3.1 (1.9)
Baseline LabsBaseline LabsN=98
Mean (±SD)N=138
Mean (±SD)
Hgb (g/dl) 11.6 (1.8) 11.6 (2.3)
PLT (103/ml) 235.4 (90.2) 234.0 (92.2)
INR 1.3 (0.3) 1.4 (0.4)
Na (mM/L) 134.1 (5.3) 134.2 (5.0)
BUN (mg/dl) 27.1 (13.9) 28.6 (14.5)
Creat (mg/dl) 1.3 (0.5) 1.4 (0.5)
Alb (g/dl) 3.5 (0.7) 3.5 (0.6)
AST (U/l) 48.2 (71.4) 51.1 (77.3)
ALT (U/l) 59.6 (92.0) 58.3 (83.9)
TBili (mg/dl) 1.1 (0.7) 1.3 (1.1)
Baseline Medical HistoryBaseline Medical HistoryN=98N (%)
N=138N (%)
Ischemic Cardiomyopathy 51 (52%) 65 (48%)
CABG 27 (28%) 33 (24%)
AICD 84 (86%) 116 (85%)
Biventricular PM 39 (40%) 59 (43%)
TIA 6 (6%) 6 (4%)
CVA 8 (8%) 11 (8%)
Diabetes Mellitus 25 (26%) 36 (27%)
IABP 38 (39%) 53 (39%)
One Inotrope 70 (73%) 98 (73%)> One Inotrope 13 (14%) 18 (13%)
Primary Endpoint (n=98)Primary Endpoint (n=98)Success Failure
Success Rate
Lower 95% Confidence
Bound (Success)N % N %
Total 77 78.6 21 21.4 78.6 69.1Transplantation 47 48 --- ---
Listed UNOS 1A/B at 180 days 30 31 --- ---
Device Replacement (<180 days) --- --- 5 5
Death --- --- 16 16
Protocol defined outcomes (only 1 per patient)
Clinical Duration of Support (n=98)Clinical Duration of Support (n=98)
All patients (N=98)
Trans-planted(N=60)
Died (N=19)
Device Replace-
ment (N=8)
On SupportΔ
(N=19)
Mean 155 134 95 216 279
Median 131 125 49 195 216
Range 1 - 574 16 - 497 1 - 403 64 - 447 64 - 574
ΔPatients on support who reached outcome
Clinical outcomes independent of protocol defined endpoints as of Jan 27, 2009 (patients may have multiple outcomes)
Study Outcomes: Interim Analysis Population (n=98)Study Outcomes: Interim Analysis Population (n=98)
Outcomes – KM Survival Curve (n=98)Outcomes – KM Survival Curve (n=98)
Patients at Risk 98 83 76 60 52 41 35
Cause of Death on LVAD SupportCause of Death on LVAD SupportDeaths (N) Deaths (%)
Bleeding – Non peri-implant 2 11LVAD Failure 1 5Multi-Organ System Failure 5 27Neurologic Stroke–Ischemic 1 5Neurologic Stroke–Hemorrhagic 1 5Other Cardiovascular 3 16 Acute MI with arrhythmias and ICD shocks 1 5 Cardiogenic shock 1 5 Congestive heart failure 1 5Sepsis 1 5Unknown Causes 1 5Other Immediate Cause of Death 4 21 Methamphetamine toxicity 1 5 Necrotic bowel 1 5 Pulmonary edema 1 5 Massive hemothorax / hemorrhagic bullae 1 5Total 19 100%
Serious Adverse EventsSerious Adverse Events
Does not include SAEs after replacement to a device other than VentrAssist
Total Support = 19435 Person-Days as of January 27, 2009
VentrAssist HeartMate II
Rate per pt-year (N=98)
Rate per pt-year (N=135)
Rate per pt-year
(N=133)Ischemic Stroke 0.10 0.11 0.13 Hemorrhagic Stroke 0.02 0.02 0.05 TIA 0.12 0.09 0.10
Major Bleeding 0.68 0.64 ---Bleeding Requiring Surgery 0.12 0.15 0.78 Bleeding Requiring ≥ 2 U --- --- 2.09 Hemolysis 0.00 0.00 0.06
VentrAssist HeartMate II
Rate per pt-year (N=98)
Rate per pt-year (N=135)
Rate per pt-year
(N=133)DM-Pump Failure 0.05 0.04 ---
Percutaneous lead 0.09 0.11 ---DM-Pump Thrombus (confirmed) 0.12 0.09 0.03
Infection-Driveline Exit 0.05 0.04 0.37 Infection-Pump Pocket 0.02 0.02 0.00 Infection-Sepsis 0.43 0.41 0.62 Renal Dysfunction (acute) 0.27 0.26 0.31Right Heart Failure 0.29 0.24 0.36
BTT Adjudicated SAEs (cont’d)BTT Adjudicated SAEs (cont’d)
Device ReplacementsDevice Replacements 8 device replacements in 8 patients 5 device replacements < 180 days on support primary reasons for replacement
Device Failure (2) Pump Thrombus (2) Percutaneous lead failure (2) Other (2): controller failure, inflow cannula
malposition Outcomes following replacement: 3 transplanted,
2 alive on support, and 3 deaths
NYHA Class Over Time (n= 138)NYHA Class Over Time (n= 138)
p-value <0.001
Minnesota Living with Heart Failure Minnesota Living with Heart Failure Questionnaire (N=138)Questionnaire (N=138)
NYHA Class Over Time (N=138)
MINNESOTA LIVING WITH HEART FAILURE QUESTIONAIRE - N=138
Better(0)
Worse (105)
p-value < 0.0001
EuroQoL (N=138)EuroQoL (N=138)
Worse (0)
Better(100)
p-value < 0.0001
• LVA3 Percutaneous lead – 6.4mm diameter• Continuous lead from pump to controller
• LVA4 Percutaneous lead - 3mm diameter• Intermediate connector and extension lead
VentrAssist LVA3 & LVA4VentrAssist LVA3 & LVA4
Lead conductor fractures reported in 11/187 LVA4 patients worldwide Cause was accidental damage [n=3] or likely stress failure where a contributing
factor was not wearing the lead support belt [n=8] No stress failures in patients wearing the lead support belt Patient outcomes include death [n=2], pump exchange [n=3] (1 later
transplanted); emergency repair [n=6] (1 later transplanted, 1 later death), Product Advisory issued to emphasize the importance of lead support belt. Additional corrective actions are under consideration
VentrAssist Inflow CannulasVentrAssist Inflow Cannulas
ConclusionsConclusionsVentrAssist LVAD exceeded performance goal at pre-specified interim analysis85% of patients transplanted or alive on support at 180 days Statistically & clinically significant improvement in QOL & functional status over duration of supportAdverse event profile similar to other current LVADs and improved over pulsatile VADsProjects ongoing to improve percutaneous lead & inflow cannula design